Pretty close to an ideal situation1.) The phase I cancer trial is going according to plan and will report in Q4. That means to me that they are not seeing toxicity issues and they will be able to give the maximum dose. If so, the chances for significant efficacy results jump considerably.
2.) The partnerring of the NASH trial tells us again that the cancer trial is looking very good. The protocol includes a mid trial look to see if it should continue. Partnerring it may not be easy and they are losing time to competitors, but NASH may drift off the radar screen entirely if the cancer results are good.
3.) Legacy drug sales were as expected. So, at elast no harm was done on that front.
4.) Great expense control and cash management.